Evidence‑Based Recommendations for PTSD Management

First‑Line Psychotherapy

Trauma‑focused cognitive‑behavioral therapies—prolonged exposure, cognitive processing therapy, and eye‑movement desensitization and reprocessing (EMDR)—are recommended as the initial treatment for chronic PTSD; selective serotonin reuptake inhibitors (SSRIs) are reserved for adjunctive or second‑line use. 1
Prolonged exposure therapy has the strongest empirical support across the broadest range of trauma‑exposed populations and has been successfully disseminated to community clinics. 2, 3
Cognitive processing therapy is strongly recommended based on robust evidence for reducing PTSD symptom severity. 1
EMDR is strongly recommended, although it has been studied less extensively than prolonged exposure and cognitive processing therapy. 1
Compared with pharmacotherapy, trauma‑focused psychotherapies produce superior long‑term outcomes and markedly lower relapse rates after treatment discontinuation. 2, 3
Implementation gap: many clinicians lack training or are reluctant to deliver exposure‑based therapies, limiting access. 2, 3
Secure video‑teleconferencing can be used to deliver trauma‑focused CBT when the modality is validated, providing an alternative when in‑person care is unavailable. 1

Sertraline and paroxetine are the only FDA‑approved medications for PTSD and are recommended as first‑line pharmacologic options. 2, 3, 1
Venlafaxine (an SNRI) is also recommended, although it does not improve hyper‑arousal symptoms. 1
Discontinuation of PTSD medications is associated with a high risk of symptom relapse, whereas gains from CBT are typically maintained after therapy ends. 2, 3

Benzodiazepines are ineffective for PTSD prevention and may increase risk: 63 % of patients receiving a benzodiazepine developed PTSD at 6 months versus 23 % with placebo. 4, 1
Cannabis‑derived products lack sufficient evidence of benefit and carry potential for harm. 1
Single‑session psychological debriefing does not prevent chronic stress reactions and is not supported by randomized trials. 2, 3, 5

Brief CBT (4–5 sessions) for individuals with high acute stress symptoms accelerates recovery and may prevent progression to chronic PTSD. 2, 3, 6
Early pharmacologic interventions (benzodiazepines, propranolol, hydrocortisone) provide limited benefit for acute stress reactions. 2, 3

Prazosin is a Level A recommendation for PTSD‑related nightmares (American Academy of Sleep Medicine). Initiate at 1 mg at bedtime and titrate by 1–2 mg every few days to an effective dose (average ≈ 3 mg, range 1–13 mg); monitor for orthostatic hypotension. 7, 8
Image Rehearsal Therapy (IRT) is also Level A recommended for nightmare disorder. 9

Recent evidence shows that trauma‑focused therapy can be delivered directly without a mandatory stabilization phase, even in patients with childhood‑abuse histories and severe comorbidity. 10
The prior assumption that individuals with complex PTSD cannot tolerate trauma‑focused interventions is not supported by current data. 10

Providing psychological debriefing within 24–72 hours after trauma does not prevent chronic PTSD. 2, 3
Using benzodiazepines for acute stress reactions may increase the risk of developing PTSD. 4
Delaying trauma‑focused therapy in favor of prolonged stabilization phases is unnecessary; direct trauma‑focused treatment is effective and safe. 10
Premature discontinuation of effective psychotherapy leads to relapse, whereas CBT benefits are typically sustained long‑term, unlike pharmacotherapy. 2, 3